• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Peptide presentation by bat MHC class I provides new insight into the antiviral immunity of bats

tetano

Editor, Senior Moderator
PLoS Biol. 2019 Sep 9;17(9):e3000436. doi: 10.1371/journal.pbio.3000436. [Epub ahead of print]
[h=1]Peptide presentation by bat MHC class I provides new insight into the antiviral immunity of bats.[/h] Lu D[SUP]1[/SUP], Liu K[SUP]1,[/SUP][SUP]2[/SUP], Zhang D[SUP]1[/SUP], Yue C[SUP]1,[/SUP][SUP]3[/SUP], Lu Q[SUP]4[/SUP], Cheng H[SUP]5[/SUP], Wang L[SUP]6[/SUP], Chai Y[SUP]6[/SUP], Qi J[SUP]6[/SUP], Wang LF[SUP]7[/SUP], Gao GF[SUP]1,[/SUP][SUP]2,[/SUP][SUP]5,[/SUP][SUP]6[/SUP], Liu WJ[SUP]1[/SUP].
[h=3]Author information[/h] 1 NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China. 2 Faculty of Health Sciences, University of Macau, Macau SAR, China. 3 Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. 4 Division of HIV/AIDS and Sex-transmitted Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China. 5 Beijing Institutes of Life Science, University of Chinese Academy of Sciences, Beijing, China. 6 CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China. 7 Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.

[h=3]Abstract[/h] Bats harbor many zoonotic viruses, including highly pathogenic viruses of humans and other mammals, but they are typically asymptomatic in bats. To further understand the antiviral immunity of bats, we screened and identified a series of bat major histocompatibility complex (MHC) I Ptal-N*01:01-binding peptides derived from four different bat-borne viruses, i.e., Hendra virus (HeV), Ebola virus (EBOV), Middle East respiratory syndrome coronavirus (MERS-CoV), and H17N10 influenza-like virus. The structures of Ptal-N*01:01 display unusual peptide presentation features in that the bat-specific 3-amino acid (aa) insertion enables the tight "surface anchoring" of the P1-Asp in pocket A of bat MHC I. As the classical primary anchoring positions, the B and F pockets of Ptal-N*01:01 also show unconventional conformations, which contribute to unusual peptide motifs and distinct peptide presentation. Notably, the features of bat MHC I may be shared by MHC I from various marsupials. Our study sheds light on bat adaptive immunity and may benefit future vaccine development against bat-borne viruses of high impact on humans.


PMID: 31498797 DOI: 10.1371/journal.pbio.3000436
Free full text
 
Back
Top Bottom